Vision & Mission

NuCapCure's mission is to revolutionise modern oncology through two ground-breaking treatments for the world's most common yet incurable brain tumour, Glioblastoma multiforme (GBM), and thus promote the well-being of global societies. The European Innovation Council (EIC) recognised the potential of the project to deliver a visionary and disruptive innovation that results into significant societal benefit and has therefore funded NuCapCure as part of the Pathfinder Open programme in Horizon Europe.

Brain Tumour Glioblastoma Multiforme

Glioblastoma multiforme is the most frequent and deadliest of the brain tumours diagnosed in almost a quarter of a million people worldwide each year with no cure to date. The current standard treatment – a combination of surgery, radiotherapy and chemotherapy – only increases the life expectancy of patients by a very short period of around 15 months, while placing a considerable physical and financial burden on those affected and on global healthcare systems.

NuCapCure Proton & NuCapCure Neutron Therapies

The seven NuCapCure partner institutions from the fields of physics, chemistry and biology are working on two radical, multimodal cancer treatments based on protons and neutrons that are specifically tailored to GBM. NuCapCure Proton and NuCapCure Neutron are designed to use the tumour's own cellular biosynthesis and turn cancer cells into a kind of intracellular mini-chemistry laboratory, thus forcing them to produce drugs. The two treatment approaches are specifically targeted to cancer cells and thus aim to protect the surrounding healthy brain tissue. They are also significantly more cost-effective than the conservative tumour therapies currently applied, especially if one considers the potential for a curative outcome.

"The NuCapCure project can revolutionise cancer treatment, aiming to offer curative yet cost-effective alternatives for GBM, providing significant benefits for patients, healthcare systems, and the society as a whole." Dr Theodossis Theodossiou – Universitetet i Oslo
NuCapCure project coordinator